Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Free Cash Flow for 8 consecutive years, with -$89.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 12.13% year-over-year to -$89.3 million; the TTM figure through Mar 2026 stood at -$249.7 million (down 4.06% YoY), while the FY2025 annual figure was -$240.1 million, down 15.78% from the prior year.
• Free Cash Flow slipped to -$89.3 million in Q1 2026 per KYMR's latest filing, from -$72.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $9.0 million in Q4 2023 and bottomed at -$89.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$46.6 million across 5 years, with a median of -$47.0 million in 2024.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 123.52% — and 2024, when it plunged 800.47%.
• Kymera Therapeutics' Free Cash Flow stood at -$38.1 million in 2022, then jumped by 123.52% to $9.0 million in 2023, then slumped by 800.47% to -$62.7 million in 2024, then declined by 15.7% to -$72.6 million in 2025, then fell by 23.02% to -$89.3 million in 2026.
• Business Quant data shows KYMR's Free Cash Flow at -$89.3 million in Q1 2026, -$72.6 million in Q4 2025, and -$27.3 million in Q3 2025.